Clinical Trial Update: Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 pilot trial evaluated rapamycin (sirolimus) for autosomal dominant polycystic kidney disease; the study completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Polycystic Kidney Diseases | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-06